BRAF and melanoma: The initial treatment for BRAF V600 mutation was monotherapy and FDA approved the first successful therapy targeting BRAF mutant melanoma called vemurafenib, an oral small molecule inhibitor of BRAF V600 mutations in 2011 (41).